Abstract:The demand for production of glycoproteins from mammalian cell culture continues with an increased number of approvals as biopharmaceuticals for the treatment of unmet medical needs. This is particularly the case for humanized monoclonal antibodies which are the largest and fastest growing class of therapeutic pharmaceuticals. This demand has fostered efforts to improve the efficiency of production as well as to address the quality of the final product. Chinese hamster ovary cells are the predominant hosts for stable transfection and high efficiency production on a large scale. Specific productivity of recombinant glycoproteins from these cells can be expected to be above 50 pg/cell/day giving rise to culture systems with titers of around 5 g/L if appropriate fed-batch systems are employed. Cell engineering can delay the onset of programmed cell death to ensure prolonged maintenance of productive viable cells. The clinical efficacy and quality of the final product can be improved by strategic metabolic engineering. The best example of this is the targeted production of afucosylated antibodies with enhanced antibody-dependent cell cytotoxicity, an important function for use in cancer therapies. The development of culture media from non-animal sources continues and is important to ensure products of consistent quality and without the potential danger of contamination. Process efficiencies may also be improved by employing disposable bioreactors with the associated minimization of downtime. Finally, advances in downstream processing are needed to handle the increased supply of product from the bioreactor but maintaining the high purity demanded of these biopharmaceuticals.

Progress in Technologies and Novel Approach for Preparing Mammary Gland Bioreactors Produced Pharmaceutical Proteins

Research Progress on Mammary Gland Bioreactor

[Transgenic Animals Bioreactors].

Advances in Research of Silk Gland Bioreactor of piggyBac-Mediated Transgenic Silkworm

Expression Systems and Species Used for Transgenic Animal Bioreactors

Progress Of Transgenic Plant As Bioreactor For Pharmaceutical Proteins

Mammalian Cell Protein Expression for Biopharmaceutical Production

Recent advances in technology supporting biopharmaceutical production from mammalian cells

Mammalian cell culture for production of recombinant proteins: A review of the critical steps in their biomanufacturing

The Expression of Recombinant Human Serum Albumin in the Mammary Gland of Transgenic Mice

The transgenic animal platform for biopharmaceutical production

Advances in Genetic Engineering of Domestic Animals

Present Situation and Prospects on Application of Plant Bioreactor in Pharmaceutical

Research Progress, Bottlenecks and Strategies in the Plant Bioreactor

Improving Protein Quantity and Quality-The Next Level of Plant Molecular Farming

Review of Recombinant Therapeutic Protein Expression in Transgenic Plants

Advances on the Expressions of Foreign Proteins in Plants

Construction and Identification of a Breast Bioreactor for Human-Derived Hypoglycemic Protein Amylin

Plant-produced biopharmaceuticals: A case of technical developments driving clinical deployment

Recent Advances in Cell Engineering for Monoclonal Antibody Production

Construction of a Recombinant Human FGF1 Expression Vector for Mammary Gland-Specific Expression in Human Breast Cancer Cells